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Abstract
Background: Epidemiological studies suggest considerable overlap between functional dyspepsia
(FD) and irritable bowel syndrome (IBS). To date, no surveys have been performed to investigate
the clinical overlap between these two disorders using Rome III criteria. Our aim was to investigate
the prevalence and risk factors for the overlap of FD and IBS based on Rome III criteria in a large
clinical sample.
Methods: Consecutive patients at the general gastroenterology outpatient clinic were requested
to complete a self-report questionnaire. FD and IBS were defined by Rome III criteria.
Results: Questionnaires were returned by 3014 patients (52.8% female, 89% response rate). FD-
IBS overlap was observed in 5.0% of the patients, while 15.2% and 10.9% of the patients were
classified as FD alone and IBS alone, respectively. Compared with non-IBS patients, the odds ratio
of having FD among IBS patients was 2.09 (95% CI: 1.68–2.59). Patients with FD-IBS overlap had
higher severity scores for the postprandial fullness symptom (2.35 ± 1.49 vs. 1.72 ± 1.59, P < 0.001)
and overall FD symptom (6.65 ± 2.88 vs. 5.82 ± 2.76, P = 0.002) than those with FD alone. The
only independent risk factor for FD-IBS overlap vs. FD alone was the presence of postprandial
fullness symptom (OR 2.67, 95% CI: 1.34–5.31).
Conclusion: Clinical overlap of FD and IBS according to Rome III criteria is very common. One
risk factor for FD-IBS overlap is the presence of postprandial fullness symptom. This study provides
clues for future pathophysiological studies of FD and IBS.
Background
A high prevalence of overlap between functional dyspep-
sia (FD) and irritable bowel syndrome (IBS) has been con-
sistently and universally reported. Epidemiological data
suggest that about 13%–87% of patients with either diag-
nosis fulfill the criteria for the other diagnosis [1]. It is
possible that there is a distinct subgroup with overlap of
FD and IBS having a generalized rather than a regional
disorder of gut with common pathophysiological mecha-
nisms.
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Different definitions of FD and IBS have been shown to
identify patients with different characteristics. The new
definition of FD according to Rome III criteria, which is
based on pathophysiological studies and factor analysis,
has resulted in a more homogenous selection of patients
and more pathophysiologically relevant symptoms. Cur-
rent activity of these two disorders indicated by Rome III
criteria, has changed the symptomatic characteristics of
FD and IBS. In addition, the discovery that the presence of
IBS does not exclude the diagnosis of any functional gas-
troduodenal disorder makes the evaluation of overlap
between FD and IBS with Rome III criteria more accurate.
Therefore, the overlap between FD and IBS according to
Rome III criteria may be different from such overlap diag-
nosed with the former criteria. No studies have been per-
formed to investigate the overlap between FD and IBS
according to Rome III criteria. Since most pathophysio-
logical studies enroll subjects from clinics, a study of the
clinical overlap of FD and IBS may provide clues and new
insights for future pathophysiological studies of both dis-
orders. The aim of the present study was to determine the
prevalence and risk factors for the clinical overlap




The setting for this study was the general gastroenterology
outpatient clinic of the first affiliated hospital of Sun Yat-
sen University in Guangzhou, China. The outpatient
clinic is an open access system since it provides primary,
secondary and tertiary level care. Patients with any gas-
trointestinal disorder may seek healthcare at this clinic.
Written informed consent was obtained from all the par-
ticipants. This study was approved by the Ethics Commit-
tee of the first affiliated hospital of Sun Yat-sen University.
Sample size calculation
Based on the 1996 epidemiologic study, the prevalence of
FD-IBS overlap in the Guangdong general population was
4% [2]. The result of the pilot study conducted in 1000
consecutive patients at the general gastroenterology out-
patient clinic of the first affiliated hospital of Sun Yat-sen
University showed that the prevalence of overlap was 6%.
Based on sample size calculations according to estab-
lished formulas [3], the minimum sample size necessary
for the current study was found to be 385 participants. As
3014 patients were enrolled in this study, the sample size
was sufficient for estimating the prevalence of FD-IBS
overlap.
Subjects and survey methods
Consecutive Chinese patients (age ≥ 18 years) who pre-
sented at the general gastroenterology outpatient clinic
were requested to fill out a self-report questionnaire. The
questionnaires were dispensed to patients by two doctors
who did not intervene in the patients' medical manage-
ment. All patients were requested to complete the ques-
tions by marking the appropriate response boxes with
ticks. They were requested to consult the two doctors if
they did not understand a question in the questionnaire.
Those who chose not to complete the questionnaire were
requested to return it. Each eligible patient was asked to
fill in the questionnaire only once during the survey
period. Patients who had major psychotic episodes, men-
tal retardation, dementia, severe visual or hearing abnor-
malities or other illnesses that might render them unable
to complete the questionnaire (e.g., stroke) and those that
had used specific drugs, including NSAIDs, steroids or
drugs affecting gastric acid secretion or gastrointestinal
motility in the 3 months prior to the investigation were
excluded.
Questionnaire
The self-report questionnaire included   demographics,
such as age and gender;   the Chinese version of the previ-
ously validated Rome III diagnostic questionnaire for
adult functional dyspepsia and irritable bowel syndrome
designed by the Rome committee by which patients were
defined as FD or IBS [4]. In the development of the Chi-
nese version of the questionnaire, the original instrument
was translated, backtranslated and tested for reproducibil-
ity in a sample of 68 patients over a 2 week period. The
intra-class correlation coefficient of the translated ques-
tionnaire for adult FD and IBS was 0.88 (95% CI:
0.84–0.92). FD patients were classified according to their
symptoms as having postprandial distress syndrome
(PDS) alone, epigastric pain syndrome (EPS) alone or
coexistence of PDS and EPS (PDS+EPS) subtypes. IBS
patients were classified, as determined by their predomi-
nant stool pattern, to be four subtypes: IBS with constipa-
tion (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-
M) and unsubtyped IBS (IBS-U);   the severity of four dif-
ferent dyspeptic symptoms (postprandial fullness, early
satiation, epigastric pain and epigastric burning) and
abdominal pain/discomfort relieved by defecation or
associated with an altered bowel habit based on a 6-point
scale [5,6] (0, none; 1, very mild, could be easily ignored
without effort; 2, mild, could be ignored with effort, but
would not influence daily activities; 3, moderate, could
not be ignored and occasionally limits daily activities; 4,
severe, could not be ignored and often limits concentra-
tion on daily activities; 5, very severe, could not be
ignored and markedly limits daily activities and often
requires rest. An overall FD symptom score was calculated
by summing the severity score of each symptom;   the fre-
quency of nine different abnormal bowel habits (fewer
than three bowel movements per week; more than three
bowel movements per day; hard or lumpy stools; loose
(mushy) or watery stools; straining during a bowel move-BMC Gastroenterology 2008, 8:43 http://www.biomedcentral.com/1471-230X/8/43
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ment; urgency; feeling of incomplete bowel movement;
passing mucus during a bowel movement; abdominal
fullness, bloating or swelling) based on a 6-point scale (0,
none; 1, < 25% of the time; 2, 25%–50% of the time; 3,
50%–75% of the time; 4, > 75% of the time, but not
always; 5, always). An overall IBS abnormal bowel habit
score was calculated by summing the frequency score of
each symptom. Patients with a history of abdominal or
gynecological surgery, gastrointestinal cancer, a docu-
mented peptic ulcer disease, ulcerative colitis, Crohn's dis-
ease, diabetes mellitus or hyperthyroidism were excluded
from diagnosis of FD or IBS.
Statistical analysis
A Student's t test was used to compare the distributions of
age and individual symptom score. Distributions of sex,
individual symptom and subtype were compared by Pear-
son's chi-square test. A bivariate logistic regression analy-
sis was carried out to measure the association between FD
and IBS. To identity the risk factors for overlap, the statis-
tical analysis involved three steps: description of variation
with all potential risk factors for overlap, univariate anal-
ysis of the probability of overlap with single independent
variables and multivariate analysis using logistic regres-
sion. A P value of 0.2 in the univariate analysis was chosen
as a cutoff point to decide whether a variable could be
included in the multivariate logistic regression analysis of
the risk of FD-IBS overlap. Odds ratios with 95% confi-
dence intervals (CIs) were computed. All the statistical
comparisons were two-sided using the 0.05 significance
level. The data were processed, and statistical analysis was




Of the 3379 eligible patients, 3014 patients completed
questionnaires (response rate 89.2%). Overall, 47.2%
(1422 patients) of the respondents were male with the
mean (± s.d.) age of 43.2 (± 15.9) years and a range of
18–97 years. Among non-respondents, 47.6% were males
with a mean (± s.d.) age of 44.0 (± 16.0) with a range of
20–95 years. There was no significant difference between
the responders and non-responders with respect to sex or
age.
Demographic and symptomatic characteristics of FD-IBS 
overlap versus FD alone and versus IBS alone
The demographic and symptomatic characteristics of
patients with FD-IBS overlap, FD alone and IBS alone are
shown in Tables 1 and 2. Overlap between FD and IBS
according to Rome III criteria was very common in clinical
practice, as summarized in Figure 1; in addition, 24.8%
(151/608) of FD patients and 31.5% (151/480) of IBS
patients fulfilled the diagnostic criteria of the other disor-
der. There was no significant difference with respect to sex
or age among FD alone, IBS alone and FD-IBS overlap
groups. The odds ratio [the ratio of the odds of having IBS
Table 1: Comparison of the demographics, FD symptoms and subtypes in the FD-IBS clinical overlap group with those of the FD alone 
group
FD-IBS overlap FD alone P
(n = 151) (n = 457)
Demographics
Age (years;   ± s.d.) 42.91 ± 14.61 42.37 ± 14.84 0.70
Female Gender (%) 79(52.3) 264(57.8) 0.24
Symptoms (%)
(score,   ±  s.d.)
Early satiation 58(38.4) 152(33.3) 0.25
(1.13 ± 1.52) (0.95 ± 1.45) 0.21
Postprandial fullness 115(76.2) 266(58.2) <0.001**
(2.35 ± 1.49) (1.72 ± 1.59) <0.001**
Epigastric pain 113(74.8) 342(74.8) 1.00
(2.24 ± 1.50) (2.42 ± 1.58) 0.22
Epigastric burning 49(32.5) 118(25.8) 0.11
(0.93 ± 1.43) (0.73 ± 1.33) 0.14
Overall symptom score 6.65 ± 2.88 5.82 ± 2.76 0.002*
Subtypes(%)
PDS alone 59(39.1) 164(35.9) 0.48
EPS alone 41(27.2) 183(40.0) 0.004*
PDS+EPS 51(33.8) 110(24.1) 0.02*
FD, functional dyspepsia; IBS, irritable bowel syndrome; PDS, postprandial distress syndrome; EPS, epigastric pain syndrome; PDS+EPS, coexistence 
of PDS and EPS;
*P < 0.05,**P < 0.001
x
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among those with FD to the odds of having IBS among
those without FD, or the ratio of the odds of having FD
among those with IBS to the odds of having FD among
those without IBS] was 2.09 (95% CI: 1.68–2.59).
More patients with PDS alone had IBS than those with
EPS alone (26.5% vs. 18.3%, P = 0.039). Patients with FD-
IBS overlap were more likely to be classified as the
PDS+EPS subtype (33.8% vs. 24.1%, P = 0.02), had more
frequent presence of the postprandial fullness symptom
(76.2% vs. 58.2%, P < 0.001) and higher severity scores
for the postprandial fullness symptom (2.35 ± 1.49 vs.
1.72 ± 1.59, P < 0.001) and overall FD symptom (6.65 ±
2.88 vs. 5.82 ± 2.76, P = 0.002) than those with FD alone.
In addition, they were less likely to be classified as the EPS
alone subtype (27.2% vs. 40.0%, P = 0.004) compared to
patients classified as FD alone (Table 1). Demographic
features and patterns of symptom and subtype were not
significantly different between patients with FD-IBS over-
lap and IBS alone (Table 2).
Potential risk factors for FD-IBS overlap
Table 1 summarizes the comparison of variables in
patients with FD-IBS overlap relative to those with FD
alone. Of the dichotomously classified potential corre-
lates of the probability of overlap, the presence of post-
prandial fullness symptom (P < 0.001), epigastric burning
symptom (P = 0.11) and EPS alone subtype (P = 0.004)
were included in the multivariate logistic regression anal-
ysis. Of these, only the presence of postprandial fullness
(OR 2.67, 95% CI: 1.34–5.31, P = 0.005) had a statisti-
cally significant and independent effect on the probability
of having overlap in the final logistic model (Table 3).
Table 2 summarizes the comparison of variables in
patients with FD-IBS overlap relative to those of patients
with IBS alone. Male gender (P = 0.17) and subtypes of
Table 2: Comparison of the demographics, IBS symptoms and subtypes of the FD-IBS clinical overlap group with those of the IBS 
alone group
FD-IBS overlap IBS alone P
(n = 151) (n = 329)
Demographics
Age (years;   ± s.d.) 42.91 ± 14.61 43.63 ± 16.21 0.63
Female Gender (%) 79(52.3) 194(59.0) 0.17
Severity score of abdominal pain or discomfort 2.95 ± 0.76 2.87 ± 0.81 0.34
Symptoms (%)
(score,   ±  s.d.)
<3 bowel movements/week 39(25.8) 79(24.0) 0.67
(1.52 ± 1.05) (1.46 ± 0.96) 0.53
>3 bowel movements/day 31(20.5) 71(21.6) 0.79
(1.33 ± 0.79) (1.48 ± 1.06) 0.08
Hard or lumpy stools 57(37.7) 109(33.1) 0.32
(1.92 ± 1.37) (1.75 ± 1.23) 0.19
Loose or watery stools 55(36.4) 134(40.7) 0.37
(1.73 ± 1.21) (1.92 ± 1.34) 0.12
Defecation straining 63(41.7) 121(36.8) 0.30
(2.04 ± 1.47) (1.91 ± 1.39) 0.36
Urgency 56(37.1) 136(41.3) 0.38
(1.87 ± 1.34) (1.98 ± 1.39) 0.39
A feeling of incomplete bowel movement 80(53.0) 156(47.4) 0.26
(2.26 ± 1.46) (2.06 ± 1.37) 0.14
Passing mucus 40(26.5) 84(25.5) 0.82
(1.40 ± 0.83) (1.46 ± 0.96) 0.52
Abdominal fullness, bloating or swelling 103(68.2) 212(64.4) 0.42
(2.66 ± 1.49) (2.54 ± 1.48) 0.42
Overall score of abnormal bowel habit 16.74 ± 6.05 16.58 ± 5.05 0.78
Subtypes (%)
IBS-C 43(28.5) 91(27.7) 0.85
IBS-D 41(27.2) 116(35.3) 0.08
IBS-M 14(9.3) 18(5.5) 0.12
IBS-U 53(35.1) 104(31.6) 0.45
FD, functional dyspepsia; IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; IBS-M, mixed IBS; IBS-U, unsubtyped 
IBS
x
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IBS-M (P = 0.12) and non-IBS-D (P = 0.08) were included
in multivariate logistic regression analysis after the univar-
iate analysis. As shown in Table 4, none of these variables
were identified as risk factors for FD-IBS clinical overlap
vs. IBS alone in the final logistic model.
Discussion
The results of the present study demonstrate that clinical
overlap between FD and IBS according to Rome III criteria
is very common and that the association is highly unlikely
to be explained by chance. In addition, the presence of
postprandial fullness symptom was shown to be a risk fac-
tor for FD-IBS overlap.
Epidemiological studies concerning the rate of FD and IBS
concurrence have demonstrated a wide range (13–87%)
of overlap between these two disorders [1,7-16]. This wide
range may be due to differences in these studies such as
the varied study populations from different countries and
different diagnostic criteria used. In Asia, Shah et al. [15]
found that 58% of subjects with IBS had dyspeptic symp-
toms, while 14% of subjects with dyspeptic symptoms
had IBS in a population-based study in Mumbai, India. In
the Guangdong province of China, Chen et al. [16]
reported that 23.7% of the subjects with dyspeptic symp-
toms had IBS, which was greater than the proportion of
subjects that lacked dyspeptic symptoms and were diag-
nosed with IBS (6.5%). Importantly, most of these studies
limited their investigation to a one-way association
between FD and IBS (e.g., FD vs. FD-IBS or IBS vs. FD-IBS)
and no study has investigated the clinical overlap between
FD and IBS using Rome III criteria. In our study, we
observed that the clinical overlap of FD and IBS was very
common in patients. The odds ratio was significantly
greater than 1.0, which indicated that there was a strong
positive association between the two disorders defined by
Rome III criteria. Thus, this study provides additional
information on the clinical overlap between FD and IBS
defined by Rome III criteria in a clinically relevant sample
in China.
Some studies [7,17] have found that patients with FD-IBS
overlap had more symptoms and subtypes of the dysmo-
tility type. Stanghellini et al. [8] found that patients with
predominantly non-painful symptoms, such as postpran-
dial fullness, nausea and vomiting, were more likely to be
diagnosed with IBS than patients that predominantly
experienced epigastric pain. Our results suggest that more
patients with PDS alone overlapped IBS than those with
EPS alone and patients with FD-IBS overlap had more
presence of postprandial fullness symptom than those
with FD alone. These findings support those reported in
the above-mentioned studies. In addition, the current
study indicates that patients with FD-IBS overlap are more
likely to be classified as the PDS+EPS subtype and less
likely to be classified as the EPS alone subtype. This find-
ing has not been previously reported. The results pre-
sented here should be confirmed and the implications
should be further explored in future epidemiological and
pathophysiological studies. In particular, our results have
shown that the symptom of postprandial fullness was sig-
nificantly associated with the clinical overlap of FD and
IBS. As several studies suggest that the pathophysiological
mechanism of FD is associated with a specific symptom or
subtype of FD [18-21], we speculate that the mechanism
that underlies the symptom of postprandial fullness (such
as delayed gastric emptying or impaired accommodation)
may play a role in the pathophysiological mechanisms of
both FD and IBS.
The prevalence of clinical overlap of functional dyspepsia  (FD) and irritable bowel syndrome (IBS) (Total number of  patients = 3014) Figure 1
The prevalence of clinical overlap of functional dys-
pepsia (FD) and irritable bowel syndrome (IBS) 
(Total number of patients = 3014).
Table 3: Multivariable analysis of risk factors for FD-IBS overlap 
and FD alone
Potential risk factors β OR P 95% CI
Postprandial fullness 0.98 2.67 0.005* 1.34–5.31
Epigastric burning 0.38 1.47 0.07 0.97–2.21
EPS alone subtype 0.15 1.16 0.66 0.59–2.29
FD, functional dyspepsia; IBS, irritable bowel syndrome; EPS, 
epigastric pain syndrome; *P < 0.05
Table 4: Multivariable analysis of risk factors for FD-IBS overlap 
and IBS alone
Potential risk factors β OR P 95% CI
Male gender 0.68 1.37 0.11 0.93–2.03
IBS-D subtype 0.64 1.44 0.10 0.93–2.22
IBS-M subtype 0.48 1.62 0.21 0.77–3.40
FD, functional dyspepsia; IBS, irritable bowel syndrome; IBS-D, IBS 
with diarrhea; IBS-M, mixed IBS;BMC Gastroenterology 2008, 8:43 http://www.biomedcentral.com/1471-230X/8/43
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Many studies have demonstrated that IBS-C patients are
more likely to exhibit overlap with FD and tend to have
more symptoms of dysmotility type than IBS-D patients
[9,10,22]. Pathophysiological research has also shown
that about 30% of IBS patients have delayed gastric emp-
tying, which may be observed more frequently in patients
with constipation-predominant IBS than in those with
diarrhea-predominant IBS [23-28]. Recently, Stanghellini
et al. [29] reported that gastric emptying was delayed in
IBS patients with concomitant FD, but not in those with
IBS alone. However, our study showed that the demo-
graphics, subtypes and symptoms of IBS did not differ
between patients with IBS-C and IBS-D and that these
were not independent risk factors of FD-IBS overlap vs.
IBS alone. Compared to previously reported findings, the
differences in the findings reported here may be attributed
to the different way of subtyping IBS according to Rome
III criteria that was performed in our study but not in pre-
vious studies. The symptom pattern and pathophysiolog-
ical mechanisms of similar subtypes defined by different
criteria (e.g., constipation-predominant IBS vs. IBS with
constipation; diarrhea-predominant IBS vs. IBS with
diarrhea) may be distinct.
The severity of symptoms is also associated with patho-
physiological mechanisms [1,18-20]. Tack et al. [1] found
that patients with FD-IBS overlap, who had a greater prev-
alence of hypersensitivity to gastric distention, suffered
from more severe FD symptoms in general as compared
with patients with FD alone. In the present study, we
asked patients to rate their symptom severity and fre-
quency on a 6-point scale. Our results indicate that
patients with overlap suffered from more severe postpran-
dial fullness symptom and overall FD symptom.
Our study has some limitations. First, all of the patients
were from one hospital. However, as the hospital provides
primary, secondary and tertiary medical care and since our
clinical sample was very large, patients from different lev-
els of care were well represented here. Thus, our study
could reflect the clinical overlap between FD and IBS that
is likely to be observed at a general gastroenterology out-
patient clinic. Our results should be confirmed by future
multi-center investigations in larger clinical samples. Sec-
ond, the diagnosis of patients in our study was not con-
firmed by objective examinations. But the standardized
diagnostic Rome III questionnaire, which has a high sen-
sitivity and specificity for diagnosing functional gastroin-
testinal disorders, is an efficient diagnostic tool, which
facilitates analysis of a large clinically relevant sample and
allows for studying the epidemiology of overlap.
To the best of our knowledge, this is the first epidemiolog-
ical investigation on the prevalence and risk factors of
clinical overlap between FD and IBS using Rome III crite-
ria. The standardized questionnaire could permit compar-
ison of our results to those of other studies. Since the
doctors in charge of this survey did not intervene with the
patients' medical management, the objectivity of ques-
tionnaires completed by patients themselves was ensured.
Conclusion
Clinical overlap of FD and IBS according to Rome III cri-
teria is very common. There is a positive association
between these two disorders. Only the presence of post-
prandial fullness symptom independently predicts FD-IBS
overlap versus FD alone. Our results suggest that there is
likely to be a common disease process in a subgroup of
patients with FD-IBS overlap. These findings may provide
some clues and new insights for future pathophysiological
studies of FD and IBS defined according to Rome III crite-
ria.
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